(Q73126318)

English

Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group

scientific article published on 01 March 1997

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9057729%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9057729%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

1 reference

based on heuristic

inferred from title

placebo-controlled trial

1 reference

based on heuristic

inferred from title

multiple sclerosis

1 reference

based on heuristic

inferred from title

author name string

F Fazekas

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9057729%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

F Deisenhammer

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9057729%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

S Strasser-Fuchs

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9057729%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

G Nahler

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9057729%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

B Mamoli

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9057729%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

language of work or name

0 references

publication date

1 March 1997

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9057729%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9057729%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

349

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9057729%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

9052

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9057729%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

589-593

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9057729%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

MS: a CNS and systemic autoimmune disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2909377-4

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2909377-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2909377-4

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose intravenous gammaglobulin for myasthenia gravis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2909377-4

7 January 2021

based on heuristic

inferred from DOI database lookup

A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2909377-4

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose intravenous immunoglobulin for multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2909377-4

7 January 2021

based on heuristic

inferred from DOI database lookup

First results of immunotherapy with immunoglobulin G in multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2909377-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Open controlled therapeutic trial of intravenous immune globulin in relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2909377-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunotherapy of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2909377-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of multiple sclerosis with IVIg: potential effects and methodology of clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2909377-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunoglobulin G immunosuppression of multiple sclerosis. Suppression of all three major lymphocyte subsets.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2909377-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of IgG for intravenous use on Fc receptor-mediated phagocytosis by human monocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2909377-4

7 January 2021

based on heuristic

inferred from DOI database lookup

The effects of intravenous immune globulin on complement-dependent immune damage of cells and tissues

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2909377-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunoglobulins promote remyelination in the central nervous system

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2909377-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved vision after intravenous immunoglobulin in stable demyelinating optic neuritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2909377-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Intravenous immunoglobulin therapy in multiple sclerosis: progress from remyelination in the Theiler's virus model to a randomised, double-blind, placebo-controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2909377-4

7 January 2021

based on heuristic

inferred from DOI database lookup

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2909377-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2909377-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2909377-4

7 January 2021

based on heuristic

inferred from DOI database lookup

A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2909377-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Intravenous gammaglobulin treatment in multiple sclerosis and experimental autoimmune encephalomyelitis: delineation of usage and mode of action

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2909377-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2909377-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2909377-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2909377-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2909377-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Indications for intravenous gammaglobulin therapy in inflammatory myopathies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2909377-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of high-dose intravenous immunoglobulin therapy on blood rheology

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2909377-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2909377-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(96)09377-4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9057729%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9057729%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q73126318&oldid=2238840287"